High-Dose UVA-1 Therapy Improves Patient-Reported Outcomes and Clinical Scores in Patients with Sclerosing Skin Disease
July 2025
in “
Journal of Investigative Dermatology
”
Studysummary This study found that high-dose UVA-1 therapy appeared to improve both patient-reported outcomes and objective clinical measures in patients with morphea and systemic sclerosis, supporting its potential efficacy for treating scleroderma.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
Read the full study on jidonline.org →